Can I Take Ashwagandha with Lantus (Insulin Glargine)?

What Is the Ashwagandha-Insulin Glargine Interaction?

The interaction between ashwagandha (Withania somnifera) and insulin glargine is pharmacodynamic rather than pharmacokinetic. Both agents reduce blood glucose through independent but additive pathways, so using them together can push glucose lower than either would alone. There is no evidence that ashwagandha alters how Lantus is absorbed, distributed, metabolized, or cleared from the body.

Why "Pharmacodynamic" Matters More Here

Pharmacokinetic interactions change drug levels. Pharmacodynamic interactions change drug effects without changing levels. With this combination, your Lantus dose is unchanged, but its glucose-lowering effect is amplified because ashwagandha is adding its own downward pressure on blood sugar. That distinction matters clinically: dose-separation timing does not protect you the way it might with a pharmacokinetic interaction.

How Each Agent Lowers Blood Glucose

Insulin glargine provides a flat, 24-hour basal insulin profile that suppresses hepatic glucose output and promotes peripheral glucose uptake. A 0.2 to 0.4 units/kg starting dose in type 2 diabetes typically brings fasting plasma glucose to the target range of 80 to 130 mg/dL outlined in the ADA Standards of Medical Care in Diabetes 2024.

Ashwagandha exerts glucose-lowering effects through at least three mechanisms studied in humans and animals: stimulation of insulin secretion from pancreatic beta cells, increased GLUT4 translocation in skeletal muscle, and reduction in cortisol that secondarily improves insulin sensitivity. A 2015 randomized controlled trial published in the Journal of the International Society of Sports Nutrition reported significant reductions in fasting blood glucose in healthy adults taking 300 mg ashwagandha root extract twice daily over eight weeks [1].

Evidence That Ashwagandha Lowers Blood Glucose

Human Clinical Trial Data

The most cited human RCT on ashwagandha and glycemia is Andallu and Radhika (2000), which enrolled 25 patients with type 2 diabetes and reported a statistically significant reduction in fasting blood glucose after 30 days of ashwagandha root powder supplementation (P<0.05) [2]. Mean fasting glucose dropped from approximately 197 mg/dL to 142 mg/dL in the treatment group, a reduction of roughly 28%.

A 2019 double-blind, placebo-controlled RCT (N=60) by Agnihotri et al. Published in Medicine found that KSM-66 ashwagandha (240 mg/day) reduced serum cortisol by 22.2% and improved self-reported stress scores at 60 days [3]. Lower cortisol independently reduces counterregulatory opposition to insulin, which translates to lower fasting glucose in patients who are insulin-resistant.

Animal and Mechanistic Data

Rodent studies consistently show withanolides and withaferin A, the primary bioactive compounds in ashwagandha root, stimulate GLUT4 gene expression in skeletal muscle and reduce gluconeogenesis in the liver. A 2009 study in Phytomedicine showed alloxan-diabetic rats receiving ashwagandha root extract achieved fasting glucose reductions comparable to the oral hypoglycemic glibenclamide [4]. While rodent data does not translate directly to humans, the mechanistic consistency across species supports the pharmacodynamic concern.

What Happens When You Stack Both

No published RCT has enrolled patients on insulin glargine specifically and randomized them to ashwagandha versus placebo. That absence of direct evidence does not mean the combination is safe without monitoring. The Natural Medicines Database rates the ashwagandha-antidiabetic drug interaction as "moderate," flagging additive hypoglycemic effects as the primary concern [5]. Given insulin is the most potent glucose-lowering agent in clinical medicine, the risk of symptomatic hypoglycemia with an additive supplement is a real clinical consideration.

The Cortisol and Thyroid Angles

Cortisol Modulation and Insulin Sensitivity

Ashwagandha is classified as an adaptogen partly because it reliably blunts the hypothalamic-pituitary-adrenal (HPA) axis response to chronic stress. Cortisol is a counter-regulatory hormone: it raises blood glucose by stimulating glycogenolysis and gluconeogenesis. Patients with type 2 diabetes who have chronically elevated cortisol tend to need higher insulin doses to compensate.

If ashwagandha reduces cortisol substantially, the counterregulatory brake on glucose-lowering is weakened. A patient who needed, say, 30 units of glargine to offset both hepatic glucose output and cortisol-driven resistance may find 30 units is now too much once cortisol normalizes. That scenario produces nocturnal hypoglycemia, which can be dangerous and is often silent.

Thyroid Hormone Effects

Ashwagandha has well-documented thyroid-stimulating properties. A 2018 randomized, double-blind, placebo-controlled trial in Journal of Alternative and Complementary Medicine (N=50) found that 600 mg/day ashwagandha root extract over eight weeks significantly raised both T3 and T4 compared to placebo (P<0.05) [6]. Elevated thyroid hormones increase basal metabolic rate, accelerate glucose turnover, and can complicate glycemic control in both directions depending on the individual.

For a patient on Lantus, a rise in thyroid hormone output caused by ashwagandha could transiently increase glucose variability before any beneficial cortisol reduction kicks in. These competing effects make glucose monitoring more, not less, important during the first 4 to 8 weeks of combined use.

Testosterone and Indirect Glycemic Effects

Ashwagandha modestly raises testosterone in men with low-normal baseline levels. A 16-week RCT published in Medicine (2019, N=43) showed a 14.7% increase in serum testosterone with 675 mg/day ashwagandha root and leaf extract [7]. Higher testosterone is associated with improved insulin sensitivity in men with type 2 diabetes, per a meta-analysis of 26 trials in Diabetes Care [8]. This is a secondary pathway through which ashwagandha may further amplify insulin glargine's glucose-lowering effect.

Who Is at Greatest Risk?

Type 1 Diabetes on Tight Basal-Bolus Control

Patients with type 1 diabetes rely on exogenous insulin for survival. They have no endogenous insulin secretion to buffer swings. Any supplement that shifts the glucose-insulin balance downward carries a higher risk profile in this population. Adding ashwagandha to a Lantus regimen in type 1 diabetes should only happen with direct, ongoing supervision from an endocrinologist and continuous glucose monitoring (CGM) in place.

Hypoglycemia Unawareness

Patients who have lost the sympathetic warning signs of hypoglycemia (shakiness, sweating, palpitations) are at risk for severe events. The ADA defines hypoglycemia unawareness as impaired awareness of hypoglycemia (IAH) and estimates it affects approximately 25% of people with type 1 diabetes and a smaller but significant proportion of people with long-standing type 2 diabetes [9]. In that group, the additive glucose-lowering from ashwagandha could push glucose to dangerous levels without warning.

Patients Already at or Below Target Fasting Glucose

If your fasting glucose is consistently running 80 to 100 mg/dL on your current Lantus dose, there is little buffer before the 70 mg/dL hypoglycemia threshold. Starting ashwagandha in that situation carries a meaningful probability of pushing values below 70 mg/dL, particularly overnight when insulin's counterregulatory response is already partially suppressed by sleep.

Monitoring Protocol If You Take Both

The following monitoring framework is recommended for patients who, in consultation with their prescriber, choose to start ashwagandha while continuing insulin glargine.

Before starting ashwagandha:

• Establish a two-week baseline of fasting glucose readings each morning before your Lantus injection.
• Record your current Lantus dose and most recent HbA1c.
• Discuss the plan explicitly with your prescribing clinician and agree on a glucose threshold (for example, two consecutive fasting readings below 90 mg/dL) that would trigger a Lantus dose reduction.

Weeks 1 to 4 after adding ashwagandha:

• Check fasting glucose every morning. Do not rely solely on how you feel.
• Check glucose at bedtime if your fasting values start trending down.
• Carry fast-acting glucose (15g glucose tablets or 4 oz juice) at all times.
• Report any fasting reading below 80 mg/dL to your prescriber the same day.

Weeks 4 to 12:

• If fasting glucose has trended downward by 15 mg/dL or more without a change in diet or activity, discuss a 10% Lantus dose reduction (round down to the nearest whole unit).
• Recheck HbA1c at 3 months.
• If glucose variability has increased without a clear cause, order free T3, free T4, and morning cortisol to evaluate whether ashwagandha has shifted either axis meaningfully.

Ongoing:

• At each quarterly diabetes visit, list ashwagandha among your current medications and supplements. The ADA recommends that clinicians assess all complementary and alternative medicine use as part of standard diabetes management [9].

Practical Dosing and Timing Considerations

Standard Ashwagandha Doses Used in Trials

Human RCTs have used doses ranging from 240 mg/day (KSM-66 extract) to 600 mg/day (full-spectrum root extract). Most glucose-lowering effects in published trials appear at 300 to 600 mg/day of a root extract standardized to at least 5% withanolides. Higher doses have not been shown to produce proportionally greater glucose reduction, but they may increase the risk of adverse effects including gastrointestinal upset.

Does Timing With Lantus Matter?

Because this is a pharmacodynamic interaction rather than a pharmacokinetic one, separating the timing of ashwagandha from your Lantus injection does not meaningfully reduce the interaction. Lantus is a 24-hour basal insulin with no pronounced peak; its glucose-lowering effect is continuous. Ashwagandha's effects on cortisol, GLUT4, and insulin secretion operate on a chronic, cumulative timescale rather than an acute post-dose peak. There is no clinically supported "safe" separation window.

Form of Ashwagandha

Root extract (KSM-66, Sensoril) is the form used in most human trials and has the most consistent evidence base. Ashwagandha leaf extracts contain higher concentrations of withaferin A and may have stronger pharmacological activity. Patients already on insulin should prefer the best-studied root extract formulations at the lower end of the evidence-based dose range (300 mg/day to start) to minimize unpredictability.

What the Guidelines Say

The ADA Standards of Medical Care in Diabetes 2024 does not address ashwagandha specifically, but Section 5 (Facilitating Positive Health Behaviors) states: "The use of supplements and complementary therapies should be discussed and documented for all people with diabetes, as several agents have glycemic activity that may alter medication requirements." [9]

The American Association of Clinical Endocrinology (AACE) 2022 Comprehensive Type 2 Diabetes Management Algorithm likewise advises that "all pharmacologically active herbal and dietary supplements should be treated as potential interactants with glucose-lowering therapy and disclosed to the treating clinician" [10].

Neither guideline prohibits ashwagandha use in patients on insulin. Both require that the use be disclosed and monitored.

When to Avoid the Combination Entirely

Certain clinical scenarios argue against combining ashwagandha with insulin glargine regardless of monitoring:

• Active or recurrent severe hypoglycemia (glucose <54 mg/dL with symptoms or <40 mg/dL at any time)
• Documented hypoglycemia unawareness without CGM coverage
• Type 1 diabetes without a specialist willing to co-manage the supplement trial
• Concurrent use of other glucose-lowering supplements (berberine, gymnema, bitter melon) that already compound the hypoglycemia risk
• Pregnancy, given the absence of safety data for ashwagandha in pregnancy and the critical importance of glucose stability for fetal outcomes

A 2021 case series in Pharmacognosy Research documented thyrotoxicosis in three patients after high-dose ashwagandha use, a finding particularly relevant for patients with diabetes who are already managing thyroid comorbidities [11].

Key Safety Signals to Watch For

Hypoglycemia symptoms: shakiness, sweating, confusion, heart pounding, or headache, especially fasting in the morning or 3 to 4 hours after a meal.

Nocturnal hypoglycemia: waking with night sweats, morning headaches, or unusually high fasting glucose (Somogyi effect from overnight lows followed by a counterregulatory spike).

Unexpected glucose improvement: if your fasting values drop by more than 15 to 20 mg/dL on average within the first month of ashwagandha without other lifestyle changes, treat this as a signal to contact your prescriber, not as a positive surprise to ignore.

A fasting glucose below 80 mg/dL on more than two consecutive mornings while on your usual Lantus dose warrants a same-day call to your prescriber.